February 2012 Briefing - Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for February 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
FDA Approves Label Changes for Statins
TUESDAY, Feb. 28 (HealthDay News) -- The recommendation to remove routine monitoring of liver enzymes is among safety label changes recently approved by the U.S. Food & Drug Administration for statins, according to a Feb. 28 Drug Safety Communication issued by the agency.
Many Obese With CKD Want to Lose Weight
MONDAY, Feb. 27 (HealthDay News) -- Many overweight patients with chronic kidney disease (CKD) want to lose weight and are utilizing weight loss methods that may further kidney damage, according to a study published online Jan. 31 in the International Journal of Obesity.
Community Health Indicators Tied to Transplant Outcomes
WEDNESDAY, Feb. 22 (HealthDay News) -- In the community setting, health indicators are significantly associated with post-kidney-transplant mortality, according to a study published online Feb 20 in the Archives of Surgery.
Highest Diabetes Death Rates Seen in Trials Selecting for CKD
WEDNESDAY, Feb. 22 (HealthDay News) -- In type 2 diabetes patients selected for randomized controlled trials (RCTs), chronic kidney disease (CKD) is associated with the highest overall risk of mortality, according to a review published online Feb. 21 in the Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease.
2002 to 2008 Saw Increase in Partial Nephrectomy Use
FRIDAY, Feb. 17 (HealthDay News) -- In the United States, the use of partial nephrectomy procedures to manage renal masses in patients with renal cell carcinoma (RCC) increased significantly from 2002 to 2008, according to research published in the March issue of The Journal of Urology.
Vitamin D Doesn't Improve Cardiac Measures in CKD Patients
WEDNESDAY, Feb. 15 (HealthDay News) -- Patients with chronic kidney disease who are treated with the active vitamin D compound, paricalcitol, for 48 weeks do not show improvement in left ventricular mass or certain measures of diastolic dysfunction, compared with patients who received placebo, according to a study published in the Feb. 15 issue of the Journal of the American Medical Association.
Racial Disparity at Many Steps of Renal Transplant Process
WEDNESDAY, Feb. 15 (HealthDay News) -- Racial disparities exist with regard to patient access to referral and evaluation for renal transplant, waitlisting, and eventual receipt of a kidney, according to research published in the February issue of the American Journal of Transplantation.